GlassScriptPhysician profile
Phillip M Johnson
NPI 1659356921
$4,553.97
in general payments reported to CMS, 2019-2025
32 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $656 · 2021: $1,450 · 2022: $1,247 · 2023: $746 · 2024: $146 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,267.07 | 2020-2025 | |
| Novo Nordisk INC | $379.56 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $359.12 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $351.61 | 2019-2022 | |
| Glaxosmithkline, LLC. | $278.68 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $235.54 | 2020-2021 | |
| Allergan, INC. | $190.14 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $184.77 | 2022 | |
| Exact Sciences Corporation | $120.90 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $120.66 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $108.14 | 2022-2023 | |
| Amgen INC. | $101.38 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $95.18 | 2021-2022 | |
| Lilly USA, LLC | $94.05 | 2021-2025 | Jardiance, Mounjaro |
| Supernus Pharmaceuticals, INC. | $74.12 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $64.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.77 | 2020-2022 | |
| Eisai INC. | $51.95 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $50.94 | 2021-2023 | Livalo, Seglentis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.61 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.50 | 2021-2023 | |
| Amarin Pharma, INC. | $44.35 | 2020 | |
| Atricure, INC. | $38.45 | 2024 | |
| Idorsia Pharmaceuticals US INC | $37.00 | 2023 | Quviviq |
| Abbott Laboratories | $34.17 | 2023-2024 | Freestyle Libre |
| Astrazeneca Pharmaceuticals LP | $30.60 | 2020 | |
| Dermira, INC. | $27.45 | 2020 | |
| Corium, LLC | $18.60 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.51 | 2025 | Voquezna |
| Zyla Life Sciences, INC. | $13.76 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.63 | 2023 | Xifaxan, Trulance |
| Endogastric Solutions, INC | $5.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.